keyword
MENU ▼
Read by QxMD icon Read
search

Dmard therapy

keyword
https://www.readbyqxmd.com/read/29205926/a-retrospective-review-of-the-persistence-on-bdmards-prescribed-for-the-treatment-of-rheumatoid-arthritis-in-the-australian-population
#1
Graeme Jones, Stephen Hall, Paul Bird, Geoff Littlejohn, Kathleen Tymms, Peter Youssef, Eric Chung, Rina Barrett, Peter Button
AIM: To describe the persistence of biologic disease modifying anti-rheumatic drugs (bDMARDs) in Australian rheumatoid arthritis (RA) patients, and assess the influence of methotrexate and other conventional DMARD (cDMARD) concomitant medications, and treatment line on bDMARD persistence and glucocorticoids usage. METHOD: RA patients, from the 10% Australian Medicare random sample, aged ≥18 for whom bDMARDs were dispensed were included. Individual sub-cutaneous (SC) anti-tumor necrosis factor-α (anti-TNFα) agents were combined as they were equivalent...
December 5, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/29205346/effect-of-disease-modifying-anti-rheumatic-drugs-on-therapeutic-outcomes-among-women-with-endometriosis
#2
Alexander Kotlyar, Shirley Shue, Xiaobo Liu, Tommaso Falcone
OBJECTIVE: To determine whether disease-modifying anti-rheumatic drugs (DMARDs) affect the use of hormonal treatments, subsequent ablative surgery, and need for pain management, including opioids, non-steroidal anti-inflammatory drugs and anti-depressants, among women with endometriosis. METHODS: In a retrospective study, data were reviewed from women with surgically confirmed endometriosis who were not treated (n=234) or treated with DMARDs for 6 weeks or more (n=25) before surgical diagnosis at a single healthcare system in the USA between 2003 and 2013...
December 4, 2017: International Journal of Gynaecology and Obstetrics
https://www.readbyqxmd.com/read/29173692/socioeconomic-and-therapy-factor-influence-on-self-reported-fatigue-anxiety-and-depression-in-rheumatoid-arthritis-patients
#3
Mirjana Lapčević, Mira Vuković, Branislav S Gvozdenović, Vesna Mioljević, Snežana Marjanović
INTRODUCTION: Fatigue, anxiety and depression are very frequent symptoms in patients with rheumatoid arthritis (RA). GOALS: In this study we evaluated the influence of socioeconomic characteristics, therapy and comorbidities on the self-reported high fatigue, anxiety and depression in patients with RA. METHOD: Multicenter cross-sectional study was performed in 22 health institutions in Serbia during the period from April-August 2014 in population of older RA patients...
November 2017: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/29166919/similar-short-term-clinical-response-to-high-dose-versus-low-dose-methotrexate-in-monotherapy-and-combination-therapy-in-patients-with-rheumatoid-arthritis
#4
Sytske Anne Bergstra, Cornelia F Allaart, Rosaline van den Berg, Arvind Chopra, Nimmisha Govind, Tom W J Huizinga, Robert B M Landewe
BACKGROUND: Aiming at rapid decrease of disease activity, there has been a trend to start with higher doses of methotrexate (MTX) in patients newly diagnosed with rheumatoid arthritis (RA), both as monotherapy and in combination with other antirheumatic drugs. We aimed to study the relationship between clinical response and MTX dose as monotherapy or combination therapy in patients with early RA. METHODS: Disease-modifying anti-rheumatic drug (DMARD)-naive patients with early RA, from a large international observational database, the METEOR database, were selected if MTX was part of their initial treatment...
November 22, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29148403/treatment-patterns-in-rheumatoid-arthritis-after-discontinuation-of-methotrexate-data-from-the-ontario-best-practices-research-initiative-obri
#5
Janet E Pope, Emmanouil Rampakakis, Mohammad Movahedi, Angela Cesta, Xiuying Li, Sandra Couto, John S Sampalis, Claire Bombardier
OBJECTIVES: In active rheumatoid arthritis (RA) patients with inadequate response to methotrexate (MTX), guidelines support adding or switching to another conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) and/or a biologic DMARD (bDMARD). The purpose of this analysis was to describe treatment practices in routine care and to evaluate determinants of regimen selection after MTX discontinuation. METHODS: Biologic-naïve patients in the Ontario Best Practice Research Initiatives registry discontinuing MTX due to primary/secondary failure, adverse events, or patient/physician decision were included...
October 23, 2017: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29142036/effect-of-glucocorticoids-on-the-clinical-and-radiographic-efficacy-of-tofacitinib-in-patients-with-rheumatoid-arthritis-a-posthoc-analysis-of-data-from-6-phase-iii-studies
#6
Christina Charles-Schoeman, Désirée van der Heijde, Gerd R Burmester, Peter Nash, Cristiano A F Zerbini, Carol A Connell, Haiyun Fan, Kenneth Kwok, Eustratios Bananis, Roy Fleischmann
OBJECTIVE: Tofacitinib has been investigated for the treatment of rheumatoid arthritis (RA) in phase III studies in which concomitant glucocorticoids (GC) were allowed. We analyzed the effect of GC use on efficacy outcomes in patients with RA receiving tofacitinib and/or methotrexate (MTX) or conventional synthetic disease-modifying antirheumatic drugs (csDMARD) in these studies. METHODS: Our posthoc analysis included data from 6 phase III studies (NCT01039688; NCT00814307; NCT00847613; NCT00853385; NCT00856544; NCT00960440)...
November 15, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/29139090/tofacitinib-a-review-in-rheumatoid-arthritis
#7
Sohita Dhillon
Tofacitinib (Xeljanz(®)) is a potent, selective JAK inhibitor that preferentially inhibits Janus kinase (JAK) 1 and JAK3. In the EU, oral tofacitinib 5 mg twice daily is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant of, one or more DMARDs. Several clinical studies of ≤ 24 months' duration showed that tofacitinib monotherapy (as first- or second-line treatment) and combination therapy with a conventional synthetic DMARD (csDMARD; as second- or third-line treatment) was effective in reducing signs and symptoms of disease and improving health-related quality of life (HR-QOL), with benefits sustained during long-term therapy (≤ 96 months)...
November 14, 2017: Drugs
https://www.readbyqxmd.com/read/29119581/risk-of-tuberculosis-comparison-in-new-users-of-antitumour-necrosis-factor-%C3%AE-and-with-existing-disease-modifying-antirheumatic-drug-therapy
#8
M-J Chan, Y-H Wen, Y-B Huang, H-Y Chuang, Y-L Tain, Y-C Lily Wang, C-N Hsu
WHAT IS KNOWN AND OBJECTIVE: Patients with rheumatic disease are at risk for infections. Evaluating antitumour necrosis factor (anti-TNF) drug-associated risk of infections requires justification of baseline risk in the population at high risk of infection. We examined the incidence of active tuberculosis (TB) and its risk factors in patients with rheumatic disease started with anti-TNF-α therapy or with existing disease-modifying antirheumatic drug (DMARD) therapy. METHODS: A retrospective cohort study of anti-TNF-α therapy new users (anti-TNF-α group) and those starting with a DMARD after the failure of at least one other DMARD or who had added to existing DMARD treatment (DMARD group) for rheumatic disease in the largest medical setting in Taiwan from 1 January 2005 through 31 November 2013 was conducted to determine relative risk of TB between patient groups...
November 8, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/29116003/protocols-on-classification-monitoring-and-therapy-in-children-s-rheumatology-pro-kind-results-of-the-working-group-polyarticular-juvenile-idiopathic-arthritis
#9
REVIEW
Gerd Horneff, Ariane Klein, Gerd Ganser, Michaela Sailer-Höck, Annette Günther, Ivan Foeldvari, Frank Weller-Heinemann
OBJECTIVE: Several effective pharmacologic treatment options for polyarticual juvenile idiopathic arthritis (JIA) have emerged but initial treatment is heterogeneous in Germany. Therefore, the German Society of Pediatric Rheumatolgy has established a commission to develop consensus "Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND)" to harmonize diagnostic and treatment approaches for new-onset JIA in Germany. METHODS: A set of definitions for in- and exclusion, diagnostic workup, parameters for the evaluation of disease activity criteria, therapeutic options, medication dosing, monitoring recommendations, targets, definitions of a therapy failure and four therapeutic algorithms developed by a working group were agreed by web based survey to which all members of the GKJR have been invited...
November 7, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/29111261/recommendations-of-the-spanish-society-of-rheumatology-on-treatment-and-use-of-systemic-biological-and-non-biological-therapies-in-psoriatic-arthritis
#10
Juan Carlos Torre Alonso, Petra Díaz Del Campo Fontecha, Raquel Almodóvar, Juan D Cañete, Carlos Montilla Morales, Mireia Moreno, Chamaida Plasencia-Rodríguez, Julio Ramírez García, Rubén Queiro
OBJECTIVE: The main purpose of this recommendation statement is to provide clinicians with the best available evidence and the best opinion agreed upon by the panelists for a rational use of synthetic disease modifying antirheumatic drugs (DMARDs) and biologicals in psoriatic arthritis (PsA) patients. The present document also focuses on important aspects in the management of PsA, such as early diagnosis, therapeutic objectives, comorbidities and optimization of treatment. METHODS: The recommendations were agreed by consensus by a panel of 8 expert rheumatologists, previously selected by the Spanish Society of Rheumatology (SER) through an open call...
October 27, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/29094311/tocilizumab-a-review-in-rheumatoid-arthritis
#11
Lesley J Scott
Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra(®)), an IL-6 receptor antagonist, are approved (± methotrexate) in numerous countries throughout the world, for the treatment of adults with moderate to severe active rheumatoid arthritis (RA). Extensive clinical experience has firmly established the short- and long-term efficacy and safety of tocilizumab [monotherapy or in combination with conventional synthetic DMARDs (csDMARDs)] in adults with early-stage and longer-duration established RA...
November 2017: Drugs
https://www.readbyqxmd.com/read/29067050/delayed-conventional-dmards-therapy-is-effective-in-rheumatoid-arthritis
#12
Tasnim Ahsan, Uzma Erum, Danish Khowaja, Assadullah Dahani
OBJECTIVE: To determine the disease severity in patients with Rheumatoid Arthritis (RA), at baseline and the impact of treatment on disease activity (DA) after six months of disease modifying anti-rheumatic drugs (DMARDs) therapy. METHODS: This prospective study was conducted at the 'Rheumatology Clinic' of Jinnah Postgraduate Medical Centre (JPMC), Karachi, from June 2014 to May 2015. A total of 111 patients, with the diagnosis of RA were included in the study...
July 2017: Pakistan Journal of Medical Sciences Quarterly
https://www.readbyqxmd.com/read/29065903/changes-in-clinical-disease-activity-are-weakly-linked-to-changes-in-mri-inflammation-on-treat-to-target-escalation-of-therapy-in-rheumatoid-arthritis
#13
Fiona M McQueen, Peter Chapman, Terina Pollock, Dena D'Souza, Arier C Lee, Nicola Dalbeth, Lisa Stamp, Karen Lindsay, Anthony Doyle
BACKGROUND: Rheumatoid arthritis (RA) treat-to-target (T2T) regimens often use the disease activity score (28 joints) incorporating C-reactive protein (DAS28CRP) as an outcome measure. We compared changes in the DAS28CRP with changes in magnetic resonance imaging (MRI) inflammation on treatment escalation. METHODS: Eighty seropositive RA patients with active disease were enrolled. Group A (N = 57) escalated to another conventional disease-modifying therapy (cDMARD) combination, and Group B (N = 23) to anti-TNF therapy/cDMARDs...
October 24, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/29056774/glucocorticoid-management-in-rheumatoid-arthritis-morning-or-night-low-dose
#14
REVIEW
Sabrina Paolino, Maurizio Cutolo, Carmen Pizzorni
Morning symptoms of rheumatoid arthritis (RA) are linked to circadian increase of night inflammation, supported by inadequate cortisol secretion in active disease. Therefore, exogenous glucocorticoid administration in RA is recommended by EULAR and ACR from the beginning of the diagnosis, since may partially act like a "replacement therapy". In addition, the prevention/treatment of the night up-regulation of the immune/inflammatory reaction has been shown more effective when exogenous glucocorticoid administration is managed with a night-time-release formulation...
2017: Reumatologia
https://www.readbyqxmd.com/read/29045964/-increased-serum-c-c-chemokine-ligand-19-levels-correlated-with-b-cell-abnormalities-in-systemic-lupus-erythematosus
#15
H J Liu, L J Shi, F L Hu, H H Yao, Z G Li, Y Jia
OBJECTIVE: To detect the levels of serum C-C chemokine ligand 19 (CCL19) in patients with systemic lupus erythematosus (SLE) and to evaluate the correlation between CCL19 expression and clinical features and laboratory parameters, trying to reveal the possible role of CCL19 in the pathogenesis of systemic lupus erythematosus. METHODS: The levels of serum CCL19 were measured by enzyme linked immunosorbent assay (ELISA) in 90 patients with SLE and 30 healthy controls...
October 18, 2017: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
https://www.readbyqxmd.com/read/29033678/quantitative-metabolic-volumetric-product-on-18-fluorine-2fluoro-2-deoxy-d-glucose-positron-emission-tomography-computed-tomography-in-assessing-treatment-response-to-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-multiparametric-analysis-integrating
#16
Nandigam Santosh Kumar, Yogesh Shejul, Ramesh Asopa, Sandip Basu
The purpose of this study was to assess the role of fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the evaluation of treatment response evaluation to disease-modifying antirheumatic drug (DMARD) therapy in patients of rheumatoid arthritis (RA). A total of ten patients with proven diagnosis of RA as per the 2010 American College of Rheumatology/European League against Rheumatism (EULAR) criteria were prospectively evaluated. All patients underwent clinical and biochemical evaluation and a baseline FDG-PET/CT with assessment of maximum standardized uptake value and metabolic volumetric product (MVP) values...
October 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/29032909/subclinical-synovitis-measured-by-ultrasound-in-rheumatoid-arthritis-patients-with-clinical-remission-induced-by-synthetic-and-biological-modifying-disease-drugs
#17
Marcos Cruces, Soham Al Snih, Natalí Serra-Bonett, Juan C Rivas
BACKGROUND: Rheumatoid arthritis (RA) patients with disease in clinical remission might show subclinical synovitis, which can be related to the progress of structural joint damage. OBJECTIVE: To determine and compare the degree of synovial inflammation by ultrasound (US) in patients with RA in clinical remission, treated with DMARD or combination therapy with DMARD and anti-TNF. METHODS: Hospital-based cross-sectional study of 58 patients with RA in sustained remission for at least 6 months by DAS28 <2...
October 9, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/29029185/patient-reported-outcomes-in-newly-diagnosed-early-rheumatoid-arthritis-patients-treated-to-target-with-a-tocilizumab-or-methotrexate-based-strategy
#18
Xavier M Teitsma, Johannes W G Jacobs, Paco M J Welsing, Attila Pethö-Schramm, Michelle E A Borm, Lidy Hendriks, Natasja H A M Denissen, Jacob M van Laar, Floris P J G Lafeber, Johannes W J Bijlsma
Objective: To evaluate the effect of initiation of tocilizumab, with or without MTX, compared with MTX alone on patient-reported outcomes (PROs), in DMARD-naïve patients with early RA. Methods: In U-Act-Early, patients initiated treat-to-target step-up MTX, tocilizumab or tocilizumab plus MTX therapy. PROs assessed included the Functional Assessment of Chronic Illness Therapy-Fatigue, 36-item Short Form (SF-36), five dimensional EuroQol (EQ-5D) and the Revised Illness Perception Questionnaire...
December 1, 2017: Rheumatology
https://www.readbyqxmd.com/read/28976302/certolizumab-pegol-and-secukinumab-for-treating-active-psoriatic-arthritis-following-inadequate-response-to-disease-modifying-antirheumatic-drugs-a-systematic-review-and-economic-evaluation
#19
Mark Corbett, Fadi Chehadah, Mousumi Biswas, Thirimon Moe-Byrne, Stephen Palmer, Marta Soares, Matthew Walton, Melissa Harden, Pauline Ho, Nerys Woolacott, Laura Bojke
BACKGROUND: Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or more synthetic disease-modifying antirheumatic drugs (DMARDs). NICE does not specifically recommend switching from one biologic to another, and only ustekinumab (UST; STELARA®, Janssen Pharmaceuticals, Inc., Horsham, PA, USA) is recommended after anti-tumour necrosis factor failure. Secukinumab (SEC; COSENTYX®, Novartis International AG, Basel, Switzerland) and certolizumab pegol (CZP; CIMZIA®, UCB Pharma, Brussels, Belgium) have not previously been appraised by NICE...
October 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28963724/the-anti-cd6-antibody-itolizumab-provides-clinical-benefit-without-lymphopenia-in-rheumatoid-arthritis-patients-results-from-a-6-month-open-label-phase-i-clinical-trial
#20
Pedro C Rodríguez, Dinorah M Prada, Ernesto Moreno, Lazaro E Aira, Claudino Molinero, Ana M Lopez, Jorge A Gómez, Isabel M Hernandez, Jose P Martinez, Yusimi Reyes, Joel M Milera, Maria V Hernandez, Roberto Torres, Yisel Avila, Yinet Barrese, Carmen Viada, Enrique Montero, Patricia Hernández
Itolizumab is a humanized anti-CD6 monoclonal antibody (mAb) that has previously shown encouraging results, in terms of safety and positive clinical effects, in a 6-week monotherapy clinical trial conducted in RA patients. The current phase I study evaluated the safety and clinical response for a longer treatment of 12 itolizumab intravenous doses in subjects with active RA despite previous DMARD therapy. Twenty one subjects were enrolled in four dose groups (0.1, 0.2, 0.4 and 0.8 mg/kg). Efficacy endpoints including American College of Rheumatology (ACR)20, ACR50 and ACR70 response rates and Disease Activity Score in 28 joints (DAS28) were monitored at baseline and at specific time points over a 10-week follow-up period...
September 30, 2017: Clinical and Experimental Immunology
keyword
keyword
2404
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"